Advanced Imaging for Barrett’s Esophagus and Early Neoplasia: Surface and Subsurface Imaging for Diagnosis and Management

被引:3
作者
Mkarimi M. [1 ]
Mashimo H. [1 ]
机构
[1] VA Boston Healthcare, Harvard Medical School, 1400 VFW Parkway, West Roxbury, 02132, MA
关键词
Barrett’s esophagus; Chromoendoscopy; Confocal laser endomicroscopy; Endoscopic imaging; Esophageal adenocarcinoma; Optical coherence tomography;
D O I
10.1007/s11894-018-0661-6
中图分类号
学科分类号
摘要
Purpose of Review: Esophageal adenocarcinoma bears one of the fastest rising incidence of any cancers and generally arises in the setting of gastroesophageal reflux and Barrett’s esophagus. However, early detection of neoplasia can be challenging since most patients are asymptomatic until they progress to more advanced and less curable stages, and early dysplastic lesions can be small, multifocal, and difficult to detect. Clearly, new imaging tools are needed in light of sampling error associated with random biopsies, the current standard of practice. Recent Findings: Advances in endoscopic imaging including virtual chromoendoscopy, confocal laser endomicroscopy, and subsurface imaging with optical coherence tomography have ushered in a new era for detecting subtle neoplastic lesions. Moreover, in light of esophagus-sparing treatments for neoplastic lesions, such tools are likely to guide ablation and follow-up management. Summary: While there is no ideal single imaging modality to facilitate improved detection, staging, ablation, and follow-up of patients with dysplastic Barrett’s esophagus, new advances in available technology, the potential for multimodal imaging, and the use of computer-aided diagnosis and biomarkers all hold great promise for improving detection and treatment. © 2018, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
引用
收藏
相关论文
共 99 条
  • [1] Castell D.O., Katzka D.A., Barrett’s esophagus: continuing questions and controversy, Gastrointest Endosc, 49, pp. S5-S8, (1999)
  • [2] Kuipers E.J., Barrett esophagus and life expectancy: implications for screening?, Gastroenterol Hepatol (N Y), 7, pp. 689-691, (2011)
  • [3] Shaheen N.J., Falk G.W., Iyer P.G., Et al., ACG clinical guideline: diagnosis and management of Barrett’s esophagus, Am J Gastroenterol, 111, pp. 30-50, (2016)
  • [4] Mashimo H., Subsquamous intestinal metaplasia after ablation of Barrett’s esophagus: frequency and importance, Curr Opin Gastroenterol, 29, pp. 454-459, (2013)
  • [5] Visrodia K., Singh S., Krishnamoorthi R., Et al., Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis, Gastroenterology, 150, pp. 599-607 e7, (2016)
  • [6] Corley D.A., Mehtani K., Quesenberry C., Et al., Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas, Gastroenterology, 145, pp. 312-319, (2013)
  • [7] Committee A.T., Wong Kee Song L.M., Adler D.G., Et al., Chromoendoscopy, Gastrointest Endosc, 66, pp. 639-649, (2007)
  • [8] Connor M.J., Sharma P., Chromoendoscopy and magnification endoscopy for diagnosing esophageal cancer and dysplasia, Thorac Surg Clin, 14, pp. 87-94, (2004)
  • [9] Breyer H.P., Silva De Barros S.G., Maguilnik I., Et al., Does methylene blue detect intestinal metaplasia in Barrett’s esophagus?, Gastrointest Endosc, 57, pp. 505-509, (2003)
  • [10] Trivedi P.J., Braden B., Indications, stains and techniques in chromoendoscopy, QJM, 106, pp. 117-131, (2013)